Price Chopper expands Diabetes AdvantEdge program with free offerings
SCHENECTADY, N.Y. Insulin-dependent diabetics will be eligible to receive free syringes and pen needles from Price Chopper, the Northeast supermarket chain said.
Price Chopper said the expansion of its Diabetes AdvantEdge program meant that it could serve 100% of the population that manages diabetes with increased access to medication, supplies, support and information, as well as education on food, nutrition and diabetes management.
“Diabetes AdvantEdge has been so well-received by those managing diabetes, as well as members of the healthcare community, that several chain drug stores have attempted to follow suit,” Price Chopper VP pharmacy Vincent Mainella said. “As a supermarket, however, we differentiate ourselves by providing a wide variety of fresh and packaged foods coupled with open access to our health professionals, registered dietitians and nutrition specialists.”
Matthew Poli joins The Emerson Group
WAYNE, Pa. The Emerson Group on Thursday announced the addition of Matthew Poli to the company, effective Sept. 20. Poli’s responsibilities will include client business development, brand management and marketing. He will work out of Emerson’s Wayne, Pa., office and will report to Rick Wellinger, Emerson president.
Poli comes to Emerson with more than 16 years of experience in marketing, sales management, trade marketing and account development — all within Johnson & Johnson’s McNeil Consumer Healthcare unit. Most recently, Poli servied as senior brand manager of children’s Tylenol and children’s Motrin. In this P&L role, Poli was responsible for growing brand equity and market share, consumer communications and innovation pipeline development, Emerson noted.
In previous marketing roles, Poli developed the strategy extending Tylenol into the external pain-relief market, ultimately leading to the launch of Precise external pain relievers. Poli also launched Tylenol PM rapid-release gels in 2008.
“We are very excited about Matthew’s role in helping us achieve our goals we have established with our business partners,” Welllinger stated. “Please join me in welcoming Matthew, his wife Beth Ann and daughter Chelsea to The Emerson Group.”
FDA advisory committee votes against Eisai-Arena obesity drug
SAN DIEGO An advisory committee of the Food and Drug Administration has given a thumbs-down to a drug for treating obesity.
Eisai and Arena Pharmaceuticals said Thursday that the FDA’s Endocrinologic and Metabolic Drugs Advisory Committee voted 9-5 to recommend against approval of the drug lorcaserin, saying clinical trial data did not adequately show that its benefits would outweigh its risks.
While the FDA is not bound by advisory committee recommendations, it takes them into account when deciding whether or not to grant approval to a drug.